{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gonadectomy&page=2",
    "query": {
      "intervention": "Gonadectomy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gonadectomy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T12:18:43.353Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01503229",
      "title": "Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2012-12",
      "completion_date": "2020-03-12",
      "has_results": true,
      "last_update_posted_date": "2021-05-14",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01503229"
    },
    {
      "nct_id": "NCT04060394",
      "title": "Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Phase I and Phase II: LAE001/prednisone + afuresertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laekna Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 49,
      "start_date": "2019-09-13",
      "completion_date": "2024-03-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060394"
    },
    {
      "nct_id": "NCT06013475",
      "title": "An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide (BAY 1841788)",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1375,
      "start_date": "2023-08-31",
      "completion_date": "2024-10-28",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06013475"
    },
    {
      "nct_id": "NCT03481816",
      "title": "Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms",
        "Prostatic Cancer"
      ],
      "interventions": [
        {
          "name": "ETBX-071; adenoviral PSA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-061; adenoviral MUC1 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-051; adenoviral brachyury vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2018-07-24",
      "completion_date": "2021-03-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03481816"
    },
    {
      "nct_id": "NCT02106507",
      "title": "ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2014-04",
      "completion_date": "2021-06-28",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106507"
    },
    {
      "nct_id": "NCT05348577",
      "title": "Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "capivasertib",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 1035,
      "start_date": "2022-03-25",
      "completion_date": "2026-03-04",
      "has_results": false,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 37,
      "location_summary": "Yuma, Arizona • Beverly Hills, California • Cerritos, California + 31 more",
      "locations": [
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05348577"
    },
    {
      "nct_id": "NCT02020135",
      "title": "An Open-label Extension Study of PSMA ADC 2301 in mCRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PSMA ADC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Progenics Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2013-10",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02020135"
    },
    {
      "nct_id": "NCT02286921",
      "title": "Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Resistant Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Testosterone cypionate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Testosterone Enanthate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 222,
      "start_date": "2015-01",
      "completion_date": "2020-02-21",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286921"
    },
    {
      "nct_id": "NCT03834506",
      "title": "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1030,
      "start_date": "2019-05-02",
      "completion_date": "2023-07-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 28,
      "location_summary": "Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03834506"
    },
    {
      "nct_id": "NCT01961843",
      "title": "Abiraterone Acetate for Castrate Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2014-01-14",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-09-23T12:18:43.353Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01961843"
    }
  ]
}